158 related articles for article (PubMed ID: 7655032)
1. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII.
Sands MS; Erway LC; Vogler C; Sly WS; Birkenmeier EH
Blood; 1995 Sep; 86(5):2033-40. PubMed ID: 7655032
[TBL] [Abstract][Full Text] [Related]
2. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates.
Sands MS; Barker JE; Vogler C; Levy B; Gwynn B; Galvin N; Sly WS; Birkenmeier E
Lab Invest; 1993 Jun; 68(6):676-86. PubMed ID: 8515654
[TBL] [Abstract][Full Text] [Related]
3. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease.
Vogler C; Sands MS; Galvin N; Levy B; Thorpe C; Barker J; Sly WS
J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337
[TBL] [Abstract][Full Text] [Related]
4. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII.
Freeman BJ; Roberts MS; Vogler CA; Nicholes A; Hofling AA; Sands MS
Blood; 1999 Sep; 94(6):2142-50. PubMed ID: 10477745
[TBL] [Abstract][Full Text] [Related]
5. Inner ear pathology in the mucopolysaccharidosis VII mouse.
Ohlemiller KK; Hennig AK; Lett JM; Heidbreder AF; Sands MS
Hear Res; 2002 Jul; 169(1-2):69-84. PubMed ID: 12121741
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.
O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS
J Clin Invest; 1998 Apr; 101(7):1394-400. PubMed ID: 9525982
[TBL] [Abstract][Full Text] [Related]
7. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation.
Ohlemiller KK; Vogler CA; Roberts M; Galvin N; Sands MS
Exp Eye Res; 2000 Nov; 71(5):469-81. PubMed ID: 11040082
[TBL] [Abstract][Full Text] [Related]
8. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency.
Soper BW; Lessard MD; Vogler CA; Levy B; Beamer WG; Sly WS; Barker JE
Blood; 2001 Mar; 97(5):1498-504. PubMed ID: 11222399
[TBL] [Abstract][Full Text] [Related]
9. Reduction of lysosomal storage in murine mucopolysaccharidosis type VII by transplantation of normal and genetically modified macrophages.
Ohashi T; Yokoo T; Iizuka S; Kobayashi H; Sly WS; Eto Y
Blood; 2000 Jun; 95(11):3631-3. PubMed ID: 10828055
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy for murine mucopolysaccharidosis type VII.
Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH
J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966
[TBL] [Abstract][Full Text] [Related]
11. Pathology of the ear in murine mucopolysaccharidosis type VII. Morphologic correlates of hearing loss.
Berry CL; Vogler C; Galvin NJ; Birkenmeier EH; Sly WS
Lab Invest; 1994 Sep; 71(3):438-45. PubMed ID: 7933993
[TBL] [Abstract][Full Text] [Related]
12. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice.
Sakurai K; Iizuka S; Shen JS; Meng XL; Mori T; Umezawa A; Ohashi T; Eto Y
Gene Ther; 2004 Oct; 11(19):1475-81. PubMed ID: 15295619
[TBL] [Abstract][Full Text] [Related]
13. Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12 months in the gus(mps/mps) and up to 18 months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII.
Derrick-Roberts AL; Pyragius CE; Kaidonis XM; Jackson MR; Anson DS; Byers S
Hum Gene Ther; 2014 Sep; 25(9):798-810. PubMed ID: 25003807
[TBL] [Abstract][Full Text] [Related]
14. AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice.
Hennig AK; Ogilvie JM; Ohlemiller KK; Timmers AM; Hauswirth WW; Sands MS
Mol Ther; 2004 Jul; 10(1):106-16. PubMed ID: 15233947
[TBL] [Abstract][Full Text] [Related]
15. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse.
Meng XL; Shen JS; Ohashi T; Maeda H; Kim SU; Eto Y
J Neurosci Res; 2003 Oct; 74(2):266-77. PubMed ID: 14515356
[TBL] [Abstract][Full Text] [Related]
16. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.
Sands MS; Vogler C; Torrey A; Levy B; Gwynn B; Grubb J; Sly WS; Birkenmeier EH
J Clin Invest; 1997 Apr; 99(7):1596-605. PubMed ID: 9120003
[TBL] [Abstract][Full Text] [Related]
17. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer.
Daly TM; Ohlemiller KK; Roberts MS; Vogler CA; Sands MS
Gene Ther; 2001 Sep; 8(17):1291-8. PubMed ID: 11571565
[TBL] [Abstract][Full Text] [Related]
18. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation.
Birkenmeier EH; Barker JE; Vogler CA; Kyle JW; Sly WS; Gwynn B; Levy B; Pegors C
Blood; 1991 Dec; 78(11):3081-92. PubMed ID: 1954394
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival.
Vogler C; Sands MS; Levy B; Galvin N; Birkenmeier EH; Sly WS
Pediatr Res; 1996 Jun; 39(6):1050-4. PubMed ID: 8725268
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for murine mucopolysaccharidosis type VII.
Sands MS; Wolfe JH; Birkenmeier EH; Barker JE; Vogler C; Sly WS; Okuyama T; Freeman B; Nicholes A; Muzyczka N; Chang PL; Axelrod HR
Neuromuscul Disord; 1997 Jul; 7(5):352-60. PubMed ID: 9267850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
